Genetic variants and risk of lung cancer in never smokers: A genome-wide association study

The Lancet Oncology

Volumn 11, Issue 4, 2010, Pages 321-330

  Li, Yafei ^a   Sheu, Chau Chyun ^b   Ye, Yuanqing ^c   de Andrade, Mariza ^a   Wang, Liang ^a   Chang, Shen Chih ^d   Aubry, Marie C ^a   Aakre, Jeremiah A ^a   Allen, Mark S ^a   Chen, Feng ^b   Cunningham, Julie M ^a   Deschamps, Claude ^a   Jiang, Ruoxiang ^a   Lin, Jie ^c   Marks, Randolph S ^a   Pankratz, V Shane ^a   Su, Li ^b   Li, Yan ^a   Sun, Zhifu ^a   Tang, Hui ^a   Vasmatzis, George ^a   Harris, Curtis C ^e   Spitz, Margaret R ^c   Jen, Jin ^a   Wang, Renyi ^d   Zhang, Zuo Feng ^d   Christiani, David C ^b,f   Wu, Xifeng ^c   Yang, Ping ^a   more..

^a Mayo Clinic   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYPICAN; GLYPICAN 5; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CHROMOSOME 13Q; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GLYPICANS; HUMANS; LINKAGE DISEQUILIBRIUM; LUNG NEOPLASMS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRINCIPAL COMPONENT ANALYSIS; REGRESSION ANALYSIS; SMOKING; UNITED STATES;

EID: 77950341944     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70042-5     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Toh CK, Lim WT Lung cancer in never-smokers. J Clin Pathol 2007, 60:337-340.
3. Sun S, Schiller JH, Gazdar AF Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007, 7:778-790.
4. Subramanian J, Govindan R Lung cancer in never smokers: a review. J Clin Oncol 2007, 25:561-570.
5. Stayner L, Bena J, Sasco AJ, et al. Lung cancer risk and workplace exposure to environmental tobacco smoke. Am J Public Health 2007, 97:545-551.
6. Risch A, Plass C Lung cancer epigenetics and genetics. Int J Cancer 2008, 123:1-7.
7. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
8. Wang Y, Broderick P, Webb E, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008, 40:1407-1409.
9. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008, 452:633-637.
10. McKay JD, Hung RJ, Gaborieau V, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008, 40:1404-1406.
11. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008, 40:616-622.
12. You M, Wang D, Liu P, et al. Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin Cancer Res 2009, 15:2666-2674.
13. Yang P, Li Y, Jiang R, Cunningham JM, Zhang F, de Andrade M A rigorous and comprehensive validation: common genetic variations and lung cancer. Cancer Epidemiol Biomarkers Prev 2010, 19:240-244.
14. Wang Y, Broderick P, Matakidou A, Eisen T, Houlston RS Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers. Carcinogenesis 2010, 31:234-238.
15. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005, 128:452-462.
16. Yang P, Sun Z, Krowka MJ, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med 2008, 168:1097-1103.
17. Hudmon KS, Honn SE, Jiang H, et al. Identifying and recruiting healthy control subjects from a managed care organization: a methodology for molecular epidemiological case-control studies of cancer. Cancer Epidemiol Biomarkers Prev 1997, 6:565-571.
18. Asomaning K, Miller DP, Liu G, et al. Second hand smoke, age of exposure and lung cancer risk. Lung Cancer 2008, 61:13-20.
19. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006, 38:904-909.
20. Patterson N, Price AL, Reich D Population structure and eigenanalysis. PLoS Genet 2006, 2:e190.
21. Ballman KV, Grill DE, Oberg AL, Therneau TM Faster cyclic loess: normalizing RNA arrays via linear models. Bioinformatics 2004, 20:2778-2786.
22. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007, 81:559-575.
23. Morley M, Molony CM, Weber TM, et al. Genetic analysis of genome-wide variation in human gene expression. Nature 2004, 430:743-747.
24. Gilad Y, Rifkin SA, Pritchard JK Revealing the architecture of gene regulation: the promise of eQTL studies. Trends Genet 2008, 24:408-415.
25. Landi MT, Dracheva T, Rotunno M, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One 2008, 3:e1651.
26. Su LJ, Chang CW, Wu YC, et al. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics 2007, 8:140.
27. Powell CA, Spira A, Derti A, et al. Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol 2003, 29:157-162.
28. Bjartveit K, Tverdal A Health consequences of sustained smoking cessation. Tob Control 2009, 18:197-205.
29. Ebbert JO, Yang P, Vachon CM, et al. Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol 2003, 21:921-926.
30. Speizer FE, Colditz GA, Hunter DJ, Rosner B, Hennekens C Prospective study of smoking, antioxidant intake, and lung cancer in middle-aged women (USA). Cancer Causes Control 1999, 10:475-482.
31. Lubin JH, Blot WJ, Berrino F, et al. Modifying risk of developing lung cancer by changing habits of cigarette smoking. Br Med J (Clin Res Ed) 1984, 288:1953-1956.
32. Veugelers M, Vermeesch J, Reekmans G, Steinfeld R, Marynen P, David G Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family. Genomics 1997, 40:24-30.
33. Blackhall FH, Merry CL, Davies EJ, Jayson GC Heparan sulfate proteoglycans and cancer. Br J Cancer 2001, 85:1094-1098.
34. Filmus J, Capurro M, Rast J Glypicans. Genome Biol 2008, 9:224.
35. De Cat B, David G Developmental roles of the glypicans. Semin Cell Dev Biol 2001, 12:117-125.
36. Filmus J Glypicans in growth control and cancer. Glycobiology 2001, 11:19R-23R.
37. Klaus A, Birchmeier W Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008, 8:387-398.
38. Powers S, Mu D Genetic similarities between organogenesis and tumorigenesis of the lung. Cell Cycle 2008, 7:200-204.
39. Reardon DA, Jenkins JJ, Sublett JE, Burger PC, Kun LK Multiple genomic alterations including N-myc amplification in a primary large cell medulloblastoma. Pediatr Neurosurg 2000, 32:187-191.
40. Neat MJ, Foot N, Jenner M, et al. Localisation of a novel region of recurrent amplification in follicular lymphoma to an approximately 6.8 Mb region of 13q32-33. Genes Chromosomes Cancer 2001, 32:236-243.
41. Ojopi EP, Rogatto SR, Caldeira JR, Barbieri-Neto J, Squire JA Comparative genomic hybridization detects novel amplifications in fibroadenomas of the breast. Genes Chromosomes Cancer 2001, 30:25-31.
42. Imoto I, Izumi H, Yokoi S, et al. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res 2006, 66:4617-4626.
43. Kirchhoff M, Bisgaard AM, Stoeva R, et al. Phenotype and 244k array-CGH characterization of chromosome 13q deletions: an update of the phenotypic map of 13q21.1-qter. Am J Med Genet A 2009, 149:894-905.
44. Baranzini SE, Wang J, Gibson RA, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009, 18:767-778.
45. Byun E, Caillier SJ, Montalban X, et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008, 65:337-344.
46. Gieger C, Geistlinger L, Altmaier E, et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet 2008, 4:e1000282.
47. Dimas AS, Deutsch S, Stranger BE, et al. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 2009, 325:1246-1250.